title: Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death?
authors.forename: Guillermo
authors.initials: G
authors.lastname: Chantada
authors.forename: Carlos
authors.initials: C
authors.lastname: Leal-Leal
authors.forename: Herve
authors.initials: H
authors.lastname: Brisse
authors.forename: Pim
authors.initials: P
authors.lastname: de Graaf
authors.forename: Rita S
authors.initials: RS
authors.lastname: Sitorus
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Qaddoumi
authors.forename: Celia B G
authors.initials: CB
authors.lastname: de Antoneli
authors.forename: Nurdan
authors.initials: N
authors.lastname: Tacyildiz
authors.forename: Sandra Luna
authors.initials: SL
authors.lastname: Fineman
authors.forename: Livia
authors.initials: L
authors.lastname: Lumbroso
authors.forename: François
authors.initials: F
authors.lastname: Doz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D011292:Premedication / Q000379:methods*; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D012175:Retinoblastoma / Q000401:mortality* / Q000556:secondary*
chemical_list: D000970:Antineoplastic Agents